Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion of patients with RA do not achieve these treatment targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Conaghan, Philip G., Mysler, Eduardo, Tanaka, Yoshiya, Da Silva-Tillmann, Barbara, Shaw, Tim, Liu, John, Ferguson, Ryan, Enejosa, Jeffrey V., Cohen, Stanley, Nash, Peter, Rigby, William, Burmester, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Benefit-Risk Assessment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053169/
https://www.ncbi.nlm.nih.gov/pubmed/33527177
http://dx.doi.org/10.1007/s40264-020-01036-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053169/
https://www.ncbi.nlm.nih.gov/pubmed/33527177
http://dx.doi.org/10.1007/s40264-020-01036-w

Ejemplares similares